WASHINGTON, D.C. — In the final hours of his tenure, a cloud of controversy enveloped the U.S. Food and Drug Administration (FDA) that threatens to reshape the landscape of public health and nicotine regulation for decades. The resignation of FDA Commissioner Dr. Marty Makary, officially confirmed on May 13, 2026, was not merely a transition of power but the catalyst for a systemic upheaval within the agency.
n
The release of a new set of guidelines, which allows e-cigarettes and nicotine pouches to bypass full safety approvals before entering the market, has sent shockwaves through the medical community and blindsided senior career officials. As legal battles loom and internal confusion reigns, the intersection of political influence, corporate lobbying, and addiction science has created a regulatory "Catch-22" with the health of millions of Americans hanging in the balance.
n
Main Facts: A Departure Marred by Mystery
n
The timeline of Dr. Makary’s exit was unconventional from the start. On May 12, 2026, the President announced the Commissioner’s resignation via Truth Social. By the following day, the FDA’s official biography had been updated to reflect the end of his term. However, it was the administrative actions taken in the shadow of this departure that have drawn the most scrutiny.
n
The newly published FDA guidelines effectively lower the barrier to entry for a wide array of nicotine delivery systems. Traditionally, the FDA has required rigorous Pre-Market Tobacco Product Applications (PMTAs) to ensure that new products are "appropriate for the protection of public health." The new policy appears to circumvent this standard, allowing devices to reach retail shelves without the exhaustive safety reviews previously mandated.
n
Most concerning to agency insiders is the lack of a clear author for these regulations. Sources within the FDA’s Center for Tobacco Products (CTP) report that senior officials responsible for regulating vaping and tobacco were not consulted. The result is a policy that appeared almost overnight, seemingly authorized by a phantom hand, leading to what staff members describe as "internal confusion" and a breakdown of the standard bureaucratic process.
n
Chronology: The Road to Regulatory Deregulation
n
To understand the current crisis, one must look back at the political promises and industry pressures that defined the year leading up to May 2026.
n
The Campaign Promise
n
During the previous year’s election cycle, the administration made "saving the vaping industry" a cornerstone of its regulatory platform. This stance was a direct response to the previous administration’s efforts to ban flavored e-cigarettes, which many in the industry argued was an overreach that harmed small businesses and limited options for adult smokers looking to quit.
n
The Makary Appointment and Conflict
n
Dr. Marty Makary was initially seen as a pragmatic choice for Commissioner. He gained acclaim for modernizing the FDA’s drug review process, particularly for rare conditions, and for his progressive stance on advancing research into therapeutic psychedelics. However, his tenure was increasingly defined by "tussles" with the White House. While Makary supported streamlining drug approvals, he remained a staunch opponent of flavored e-cigarettes, citing their appeal to minors.
n
The Final Week
n
As May 2026 approached, the pressure on Makary intensified. Reports suggest the administration pushed for a more "industry-friendly" approach to nicotine pouches and flavored vapes. On May 12, the resignation was made public. By May 13, as Makary was cleaning out his office, the new guidelines were uploaded to the FDA’s digital registry—a move that effectively bypassed the opposition Makary had voiced throughout his term.
n
Supporting Data: Big Tobacco’s Influence and the Science of Addiction
n
The sudden policy shift does not exist in a vacuum. Financial and behavioral data provide a clearer picture of the forces at play.
n
The Financial Trail
n
According to reports from PBS News, major tobacco conglomerates, including Reynolds American and Altria, have played a significant role in the current administration’s political landscape. These companies have contributed millions of dollars to political action committees (PACs) supporting the President’s priorities. Notably, these contributions were not limited to campaign funds but extended to the President’s inauguration and specialized projects, such as a proposed White House ballroom.
n
Both Reynolds American and Altria have pivoted their business models toward "harm reduction" products, investing billions into e-cigarettes and nicotine pouches. The new FDA guidelines directly benefit these investments by reducing the time and cost required to bring new flavored products to market.
n
The "Displacement" Theory of Addiction
n
While the political narrative focuses on economics, the medical narrative focuses on the nature of addiction itself. Dr. Robert Pretlow, a pediatrician and the publisher of AddictionNews, offers a nuanced perspective on why vaping is so difficult to regulate.
n
In his paper, "A Unified Theory of Addiction," Dr. Pretlow argues that the primary driver of vaping is not necessarily the chemical addiction to nicotine, but rather a "displacement action."
n
"People aren’t addicted to nicotine but rather to the displacement action of vaping," Dr. Pretlow asserts. "The behavior of slow inhaling and exhaling is soothing, as is the hand-to-mouth motion. Nicotine acts as the cue."
n
This theory explains why nicotine patches and gums often fail where vaping succeeds. The physical act of vaping mimics the stress-relief mechanism of smoking. This creates a paradox for regulators: while vaping is undoubtedly less toxic than combustible tobacco, its effectiveness as a "soothing behavior" makes it highly addictive, particularly for those using it to manage stress.
n
The Youth Vaping Paradox
n
Data from the CDC and FDA suggests that underage vaping in the U.S. has actually fallen to its lowest level in a decade. This success has been attributed to strict enforcement against flavored products and effective public health campaigns. Critics of the new FDA guidelines argue that by reintroducing flavored products under the guise of "adult smoking cessation," the agency is risking a resurgence in youth nicotine initiation.
n
Official Responses: A Growing Legal Rebellion
n
The response to the "phantom" guidelines was swift and litigious. On July 14, 2026, a coalition of public health organizations led by the American Academy of Pediatrics (AAP) filed a lawsuit against the administration.
n
The AAP Lawsuit
n
The AAP alleges that the FDA violated the Administrative Procedure Act by issuing these guidelines without prior notice or the opportunity for public comment. Dr. Benjamin Hoffman, President of the AAP, stated that the organization has long opposed the use of flavors—including menthol—in any tobacco or nicotine products.
"Congress banned flavors other than menthol in traditional cigarettes in 2009 for a reason," the AAP noted in a recent publication. "Flavors are a gateway that lures children into a lifetime of addiction. To allow them back onto the market without safety approvals is a dereliction of duty."
The Truth Initiative
Joining the lawsuit is the Truth Initiative, the non-profit organization famous for its "TRUTH" anti-smoking campaigns. The organization has pivoted its focus to vaping in recent years, launching the Vaping: Know the Truth curriculum in 2021.
The Truth Initiative points to the success of its "This Is Quitting" text messaging program, which has reportedly increased quit rates among young adults aged 18-24 by nearly 40%. They argue that the new FDA policy undermines these evidence-based cessation efforts by making addictive products more accessible and appealing.
Implications: The Future of Nicotine Regulation
The current situation at the FDA suggests a fundamental shift in how the U.S. government balances corporate interests against public health. The implications are three-fold:
1. The Erosion of Agency Independence
The fact that a major policy change could be enacted without the knowledge or consent of senior career staff suggests a significant erosion of the FDA’s independence. If regulations can be "ghost-written" by political appointees or industry lobbyists, the agency’s credibility as a science-led institution is in jeopardy.
2. The Technological "Sokescreen"
The FDA has defended the new guidelines by pointing to "digital age-verification technology" as a safeguard. The theory is that advanced tech will keep fruit-flavored vapes out of the hands of minors while allowing adults access. However, public health experts are skeptical, noting that tech-savvy youth have historically found ways around such barriers.
3. The "Substitution" Strategy
Big Tobacco’s strategy appears to be one of "substitution." By marketing e-cigarettes as the solution to tobacco addiction, they are essentially betting against their own traditional products. However, as noted by researchers, they "win either way." If a user switches from cigarettes to vapes, the company retains a customer. If the user uses both, the company doubles its market share.
Conclusion
The departure of Dr. Marty Makary marks a turning point for the FDA. What was once a slow, methodical process of safety review has been replaced by a chaotic, politically charged environment where the rules of the game can change overnight.
As the lawsuit from the AAP and Truth Initiative moves through the courts, the central question remains: Is the FDA’s new policy a legitimate attempt at harm reduction for adult smokers, or is it a calculated concession to an industry that has spent millions to regain its foothold in the American market? For now, the "phantom" regulations stand, and the next generation of nicotine products is already beginning to flood the shelves.
Written by Steve O’Keefe. First published August 12, 2026.
Sources:
- "FDA move allowing more e-cigarettes and nicotine pouches into U.S. blindsides officials," PBS News, May 22, 2026.
- "Resigns After Trump Pressure," Health Day News, May 18, 2026.
- "AAP, public health organizations sue FDA over policy allowing tobacco vaping products," AAP News, July 15, 2026.
- "A Unified Theory of Addiction," Dr. Robert Pretlow, Qeios.
